Chronological Analysis of First-in-Class Drugs Approved from 2011 to 2022: Their Technological Trend and Origin
The discovery and development of first-in-class (FIC) drugs are becoming increasingly important due to increasing reimbursement pressure and personalized medication. To investigate the technological trends and origin of FIC drugs, the FIC drugs approved in the U.S. from January 2011 to December 2022...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-06-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/15/7/1794 |
| _version_ | 1797587778459926528 |
|---|---|
| author | Ryo Okuyama |
| author_facet | Ryo Okuyama |
| author_sort | Ryo Okuyama |
| collection | DOAJ |
| description | The discovery and development of first-in-class (FIC) drugs are becoming increasingly important due to increasing reimbursement pressure and personalized medication. To investigate the technological trends and origin of FIC drugs, the FIC drugs approved in the U.S. from January 2011 to December 2022 were analyzed. The analysis shows that previous major target families, viz. enzymes, G-protein coupled receptors, transporters, and transcription factors, are no longer considered major in recent years. Instead, the shares of secreted proteins/peptides and mRNAs have continuously increased from 2011–2014 to 2019–2022, suggesting that the target family of FIC drugs has shifted to molecules previously considered challenging as drug targets. Small molecules were predominant in 2011–2014, followed by a large increase in antibody medicines in 2015–2018 and further diversification of antibody medicine modalities in 2019–2022. Nucleic acid medicine has also continuously increased its share, suggesting that diversifying modalities supports the creation of FIC drugs toward challenging target molecules. Over half of FIC drugs were created by small and medium enterprises (SMEs), especially young companies established in the 1990s and 2000s. All SMEs that produced more than one FIC drug approved in 2019–2022 have the strong technological capability in a specific modality. Investment in modality technologies and facilitating mechanisms to translate academic modality technologies to start-ups might be important for enhancing FIC drug development. |
| first_indexed | 2024-03-11T00:44:38Z |
| format | Article |
| id | doaj.art-2af1767fd5e54b249c1796eb496af1fa |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-11T00:44:38Z |
| publishDate | 2023-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-2af1767fd5e54b249c1796eb496af1fa2023-11-18T20:53:56ZengMDPI AGPharmaceutics1999-49232023-06-01157179410.3390/pharmaceutics15071794Chronological Analysis of First-in-Class Drugs Approved from 2011 to 2022: Their Technological Trend and OriginRyo Okuyama0College of International Management, Ritsumeikan Asia Pacific University, Beppu 874-8577, JapanThe discovery and development of first-in-class (FIC) drugs are becoming increasingly important due to increasing reimbursement pressure and personalized medication. To investigate the technological trends and origin of FIC drugs, the FIC drugs approved in the U.S. from January 2011 to December 2022 were analyzed. The analysis shows that previous major target families, viz. enzymes, G-protein coupled receptors, transporters, and transcription factors, are no longer considered major in recent years. Instead, the shares of secreted proteins/peptides and mRNAs have continuously increased from 2011–2014 to 2019–2022, suggesting that the target family of FIC drugs has shifted to molecules previously considered challenging as drug targets. Small molecules were predominant in 2011–2014, followed by a large increase in antibody medicines in 2015–2018 and further diversification of antibody medicine modalities in 2019–2022. Nucleic acid medicine has also continuously increased its share, suggesting that diversifying modalities supports the creation of FIC drugs toward challenging target molecules. Over half of FIC drugs were created by small and medium enterprises (SMEs), especially young companies established in the 1990s and 2000s. All SMEs that produced more than one FIC drug approved in 2019–2022 have the strong technological capability in a specific modality. Investment in modality technologies and facilitating mechanisms to translate academic modality technologies to start-ups might be important for enhancing FIC drug development.https://www.mdpi.com/1999-4923/15/7/1794first-in-classmodalitytarget familyoriginsmall & medium enterprise |
| spellingShingle | Ryo Okuyama Chronological Analysis of First-in-Class Drugs Approved from 2011 to 2022: Their Technological Trend and Origin Pharmaceutics first-in-class modality target family origin small & medium enterprise |
| title | Chronological Analysis of First-in-Class Drugs Approved from 2011 to 2022: Their Technological Trend and Origin |
| title_full | Chronological Analysis of First-in-Class Drugs Approved from 2011 to 2022: Their Technological Trend and Origin |
| title_fullStr | Chronological Analysis of First-in-Class Drugs Approved from 2011 to 2022: Their Technological Trend and Origin |
| title_full_unstemmed | Chronological Analysis of First-in-Class Drugs Approved from 2011 to 2022: Their Technological Trend and Origin |
| title_short | Chronological Analysis of First-in-Class Drugs Approved from 2011 to 2022: Their Technological Trend and Origin |
| title_sort | chronological analysis of first in class drugs approved from 2011 to 2022 their technological trend and origin |
| topic | first-in-class modality target family origin small & medium enterprise |
| url | https://www.mdpi.com/1999-4923/15/7/1794 |
| work_keys_str_mv | AT ryookuyama chronologicalanalysisoffirstinclassdrugsapprovedfrom2011to2022theirtechnologicaltrendandorigin |